Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Neurodex: Phase II data; Phase III for pseudobulbar effect

In an open-label, dose-escalation U.S. Phase II trial in 36 patients, Neurodex-treated patients had

Read the full 141 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE